April 5-10th, 2024 AACR (American Association for Cancer Research) Annual Conference was held in San Diego, USA. This is one of the largest cancer research conferences in the world, attracted more than 22,500 oncologists, research scientists and entrepreneurs. At the meeting, Dr. Li Ying, CSO of CD BioPharma presented two high-profile research posters related to our PD-1Ab21-CAR-T project, received wide attention and generated good discussions.
Left, Dr. Li Ying; Right, Dr. Shi Bin (Proximal Ventures)
Acute B Lymphocytic leukemia IIT results
We presented our design of PD-1Ab21 armored CAR-T and its in vitro validation results. In addition, we also presented the IIT results of the PD-1Ab21-CD19CAR-T in the treatment of refractory and recurrent acute B Lymphocytic leukemia. At present, 10 patients with leukemia were enrolled in the group. Among these 10 patients, 5 are remission-relapsed after receiving allogeneic hematopoietic stem cell transplantation. And 4 cases showed CNS infiltration and symptoms. What's exciting is that all patients receiving PD-1Ab21-CD19CAR-T achieved complete remission (CR) and/or disappearance of CNS symptoms, usually within three weeks of treatment. These results bring new hopes for patients with leukemia, especially those with CNS invasions.
Researchers are attracted to the presentations
